


## E2730

|                    |   |
|--------------------|---|
| Cat. No.:          | HY-155238   |
| CAS No.:           | 1520073-91-9  |
| Molecular Formula: | C <sub>9</sub> H <sub>8</sub> F <sub>4</sub> N <sub>2</sub> O <sub>2</sub> S              |
| Molecular Weight:  | 284.23  |
| Target:            | GABA Receptor   |
| Pathway:           | Membrane Transporter/Ion Channel; Neuronal Signaling                                      |
| Storage:           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                           |  |
|---------------------------|--|
| Description               | E2730 is a noncompetitive but selective inhibitor of gamma-aminobutyric acid (GABA) transporter 1 (GAT1) with orally available and antiepileptic activity. E2730-mediated GAT1 inhibition is positively correlated with environmental GABA levels and selectively inhibits GAT1-mediated GABA uptake. E2730 (5-50 mg/kg; po) in rat amygdala ignition model, and in mouse cornea ignition (5-50 mg/kg), drug resistance 6Hz-44mA has demonstrated in vivo efficacy in models of psychomotor epilepsy (5-50 mg/kg), fragile X syndrome (2.5-300 mg/kg), and Dravet syndrome (10 mg/kg, 20 mg/kg) <sup>[1]</sup> . |
| IC <sub>50</sub> & Target | γ-aminobutyric acid (GABA) transporter 1 (GAT1) <sup>[1]</sup>   |

### REFERENCES

[1]. Fukushima K, et al. Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti-seizure medication. *Epilepsia Open*. 2023 Sep;8(3):834-845..

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA